For patients living with primary biliary cholangitis (PBC), a rare autoimmune liver disease, an often-overlooked symptom has plagued their existence, an intense, maddening internal itch that cannot be relieved by…
GSK has announced a significant advancement in liver disease treatment with FDA approval of Lynavoy (linerixibat), marking the first medication specifically approved in the United States for treating cholestatic pruritus…
Arexvy Now Available for Adults Aged 18–49 with Certain Health Conditions The U.S. Food and Drug Administration has granted approval to expand GSK's Arexvy respiratory syncytial virus (RSV) vaccine to…
GlaxoSmithKline has achieved a significant regulatory milestone as China's National Medical Products Administration granted priority review status to linerixibat, an investigational treatment for cholestatic pruritus associated with primary biliary cholangitis.…
GSK announced a significant milestone in respiratory medicine as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Nucala (mepolizumab) for treating uncontrolled…
The landscape of HIV treatment continues to evolve, and a significant milestone has just been reached with the FDA’s approval of Rukobia (fostemsavir), a novel therapy from ViiV Healthcare. Reported…
The U.S. Food and Drug Administration (FDA) has approved GSK's combination meningococcal vaccine, Penmenvy, for individuals aged 10 to 25 as reported by Biopharma Dive. This vaccine offers protection against…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
